PFA Pension Forsikringsaktieselskab Makes New Investment in Elevance Health, Inc. $ELV

PFA Pension Forsikringsaktieselskab bought a new position in Elevance Health, Inc. (NYSE:ELV) during the 4th quarter, HoldingsChannel.com reports. The fund bought 187,317 shares of the company’s stock, valued at approximately $65,336,000.

Several other hedge funds also recently bought and sold shares of ELV. Artisan Partners Limited Partnership increased its position in Elevance Health by 24.5% in the 3rd quarter. Artisan Partners Limited Partnership now owns 4,576,805 shares of the company’s stock worth $1,478,857,000 after purchasing an additional 901,626 shares during the last quarter. First Eagle Investment Management LLC increased its position in Elevance Health by 25.0% in the 3rd quarter. First Eagle Investment Management LLC now owns 3,998,603 shares of the company’s stock worth $1,292,029,000 after purchasing an additional 798,457 shares during the last quarter. Brave Warrior Advisors LLC increased its position in Elevance Health by 65.3% in the 3rd quarter. Brave Warrior Advisors LLC now owns 1,834,002 shares of the company’s stock worth $592,603,000 after purchasing an additional 724,349 shares during the last quarter. Baupost Group LLC MA increased its position in Elevance Health by 114.1% in the 3rd quarter. Baupost Group LLC MA now owns 1,319,000 shares of the company’s stock worth $426,195,000 after purchasing an additional 703,000 shares during the last quarter. Finally, Hotchkis & Wiley Capital Management LLC increased its position in Elevance Health by 44.2% in the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 2,045,480 shares of the company’s stock worth $660,935,000 after purchasing an additional 627,038 shares during the last quarter. 89.24% of the stock is owned by institutional investors and hedge funds.

Elevance Health Price Performance

NYSE ELV opened at $372.78 on Friday. Elevance Health, Inc. has a twelve month low of $273.71 and a twelve month high of $424.24. The company has a debt-to-equity ratio of 0.70, a quick ratio of 1.48 and a current ratio of 1.48. The stock has a market capitalization of $80.95 billion, a PE ratio of 15.86, a P/E/G ratio of 2.12 and a beta of 0.66. The stock has a 50-day simple moving average of $310.69 and a 200 day simple moving average of $331.77.

Elevance Health (NYSE:ELV) last issued its quarterly earnings results on Wednesday, April 22nd. The company reported $12.58 earnings per share (EPS) for the quarter, beating the consensus estimate of $10.74 by $1.84. Elevance Health had a return on equity of 15.58% and a net margin of 2.62%.The firm had revenue of $49.49 billion for the quarter, compared to analyst estimates of $48.21 billion. During the same period in the previous year, the company posted $11.97 earnings per share. The company’s quarterly revenue was up 1.5% compared to the same quarter last year. Elevance Health has set its FY 2026 guidance at 19.850- EPS. Research analysts anticipate that Elevance Health, Inc. will post 26.79 EPS for the current year.

Elevance Health Dividend Announcement

The company also recently declared a quarterly dividend, which will be paid on Thursday, June 25th. Investors of record on Wednesday, June 10th will be paid a dividend of $1.72 per share. This represents a $6.88 annualized dividend and a yield of 1.8%. The ex-dividend date is Wednesday, June 10th. Elevance Health’s payout ratio is currently 29.26%.

Wall Street Analysts Forecast Growth

Several brokerages have weighed in on ELV. Wolfe Research set a $425.00 target price on Elevance Health and gave the stock an “outperform” rating in a research report on Thursday, January 8th. Bank of America upgraded Elevance Health from a “neutral” rating to a “buy” rating and upped their price target for the stock from $405.00 to $435.00 in a research note on Wednesday. Truist Financial decreased their price target on Elevance Health from $390.00 to $375.00 and set a “buy” rating for the company in a research note on Monday, April 13th. Barclays upped their price target on Elevance Health from $393.00 to $408.00 and gave the stock an “overweight” rating in a research note on Friday, April 24th. Finally, Robert W. Baird upped their price target on Elevance Health from $317.00 to $331.00 and gave the stock a “neutral” rating in a research note on Thursday, April 23rd. Thirteen analysts have rated the stock with a Buy rating and ten have given a Hold rating to the stock. According to MarketBeat.com, Elevance Health has a consensus rating of “Moderate Buy” and a consensus price target of $384.58.

Elevance Health Company Profile

Elevance Health, Inc (NYSE: ELV) is a large U.S.-based health benefits company that provides a broad range of health insurance products and related services. Headquartered in Indianapolis, the company rebranded from Anthem, Inc to Elevance Health in 2022 while continuing to operate consumer-facing health plans under established state and national brands. Gail Boudreaux serves as chief executive officer and president, leading the company’s strategic focus on integrated health care and benefit delivery.

Elevance’s core activities include offering medical and specialty health plans for individuals, employers and government programs, including Medicare and Medicaid managed-care products.